Integrative Network Pharmacology and ADMET Modeling Reveal the Multitarget Therapeutic Potential of Geraniol
Drugs and Drug Candidates · 22.07.2026 · 5 (3) · 41
DOI: 10.3390/ddc5030041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 22.07.2026. Verfasst von Mateus Henrique de Almeida da Costa und 2 weiteren Autor:innen. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Postgraduate Program in Biotechnology.
Abstract (Originalsprache)
Background
Geraniol is an acyclic monoterpene widely distributed in the essential oils of aromatic species such as Cymbopogon citratus, Pelargonium graveolens, and Rosa damascena, It is known for its antioxidant, anti-inflammatory, neuroprotective, and antitumor activities.
Methods
This study aimed to investigate, through network pharmacology and computational ADMET modeling, the molecular mechanisms and pharmacological potential of geraniol, integrating drug-likeness parameters, toxicity prediction, and multitarget interactions.
Results
A total of 25 core targets were identified, mainly involved in inflammation, oxidative stress, apoptosis, and transcriptional regulation. Geraniol exhibited a favorable drug-likeness profile, high predicted intestinal absorption, and low systemic toxicity, supporting its pharmaceutical applicability. Mechanistically, it modulates the Nrf2/HO-1 ↔ NF-κB axis, reducing reactive oxygen species, pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and apoptotic markers (caspases, Bax), while enhancing antioxidant enzymes (SOD, CAT, GPx) and antiapoptotic proteins (Bcl-2).
Conclusions
These findings confirm its multitarget and pleiotropic nature, highlighting its potential as a therapeutic candidate for inflammatory, metabolic, and neurodegenerative disorders. Furthermore, this study provides a robust mechanistic rationale for future in vitro and in vivo validation, as well as for the design of nanostructured formulations to improve geraniol’s bioavailability and therapeutic safety.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Postgraduate Program in Biotechnology
Zitieren
APA
Costa, M. H. D. A. D., Filgueiras, L. A., & Mendes, A. N. (2026). Integrative Network Pharmacology and ADMET Modeling Reveal the Multitarget Therapeutic Potential of Geraniol. Drugs and Drug Candidates, 5(3), 41. https://doi.org/10.3390/ddc5030041
Vancouver
Costa MHDAD, Filgueiras LA, Mendes AN. Integrative Network Pharmacology and ADMET Modeling Reveal the Multitarget Therapeutic Potential of Geraniol. Drugs and Drug Candidates. 2026;5(3):41. doi:10.3390/ddc5030041
BibTeX
@article{Costa2026,
author = {Costa, Mateus Henrique de Almeida da and Filgueiras, Lívia Alves and Mendes, Anderson Nogueira},
title = {Integrative Network Pharmacology and ADMET Modeling Reveal the Multitarget Therapeutic Potential of Geraniol},
journal = {Drugs and Drug Candidates},
year = {2026},
volume = {5},
number = {3},
pages = {41},
doi = {10.3390/ddc5030041}
}
EUVIMED